featured
Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients With Chronic Kidney Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Lancet Diabetes Endocrinol 2023 Dec 04;[EPub Ahead of Print], The EMPA-KIDNEY Collaborative GroupFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.